Cullinan Therapeutics (CGEM) Expected to Release Earnings on Thursday

Cullinan Therapeutics (NASDAQ:CGEM) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Cullinan Therapeutics to announce earnings of ($0.7993) per share and revenue of $3.6670 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 9:30 AM ET.

Cullinan Therapeutics (NASDAQ:CGEM) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.09. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Price Performance

CGEM opened at $17.55 on Wednesday. The company has a fifty day moving average price of $16.47 and a 200-day moving average price of $14.68. The firm has a market capitalization of $1.08 billion, a P/E ratio of -5.22 and a beta of 0.01. Cullinan Therapeutics has a one year low of $5.68 and a one year high of $19.43.

Insider Activity

In related news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction on Monday, July 6th. The shares were sold at an average price of $17.82, for a total transaction of $142,560.00. Following the transaction, the insider owned 162,844 shares of the company’s stock, valued at approximately $2,901,880.08. This trade represents a 4.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.60% of the company’s stock.

Institutional Trading of Cullinan Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Virtus Investment Advisers LLC grew its stake in shares of Cullinan Therapeutics by 75.5% during the fourth quarter. Virtus Investment Advisers LLC now owns 22,318 shares of the company’s stock valued at $231,000 after buying an additional 9,604 shares during the last quarter. Fox Run Management L.L.C. boosted its holdings in Cullinan Therapeutics by 36.6% during the 4th quarter. Fox Run Management L.L.C. now owns 21,204 shares of the company’s stock valued at $219,000 after acquiring an additional 5,676 shares during the period. AlphaCentric Advisors LLC bought a new position in Cullinan Therapeutics during the 4th quarter worth approximately $197,000. Schonfeld Strategic Advisors LLC purchased a new position in Cullinan Therapeutics in the 4th quarter worth approximately $172,000. Finally, Caption Management LLC increased its stake in Cullinan Therapeutics by 107.0% in the 3rd quarter. Caption Management LLC now owns 28,389 shares of the company’s stock worth $168,000 after purchasing an additional 435,062 shares during the period. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CGEM has been the subject of several research analyst reports. BTIG Research lifted their price objective on Cullinan Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. Wedbush reissued an “outperform” rating and set a $37.00 price objective on shares of Cullinan Therapeutics in a report on Thursday, June 11th. HC Wainwright reissued a “buy” rating and set a $30.00 price objective on shares of Cullinan Therapeutics in a report on Monday, June 8th. Finally, Wall Street Zen cut shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Cullinan Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $32.14.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.